H.C. Wainwright Reaffirms Buy Rating for Halozyme Therapeutics (NASDAQ: HALO) Amid Strong Financial Performance

• Analyst firm H.C. Wainwright reaffirmed its Buy rating for Halozyme Therapeutics (NASDAQ: HALO), citing strong financial results and a strategic shift towards a high-margin royalty platform.
• The biotechnology company demonstrated robust growth in Q2 2026, with overall revenue up by 48% and key royalty revenue increasing by 50%, leading to raised financial goals.
• Halozyme Therapeutics maintains a strong financial standing with an impressive EBITDA margin of 68%, indicating significant operating profit and cash generation.

On September 2, 2026, analyst firm H.C. Wainwright confirmed its Buy rating for Halozyme Therapeutics. This biotechnology company focuses on drug delivery technologies. Halozyme Therapeutics is shifting its strategy to become a high-margin royalty platform, earning money from other companies that use its technology.

The positive rating reflects Halozyme Therapeutics' strong financial results. In the second quarter of 2026, the company saw its revenue grow by 48% compared to the previous year. Its royalty revenue, a key part of its new strategy, increased by 50%. This performance led the company to raise its financial goals for the full year.

Halozyme Therapeutics' profitability is also improving. The company's EBITDA margin reached 68%. EBITDA is a measure of a company's operating profit, showing how much cash it generates from its core business before interest, taxes, depreciation, and amortization. This high margin supports the company's strong financial standing.

This outlook is further supported by other analysts. According to Zacks Investment Research, Halozyme Therapeutics is a solid growth stock with strong attributes. The company is also actively engaging with investors. Its executives are scheduled to attend conferences hosted by Wells Fargo, Morgan Stanley, and H.C. Wainwright in September 2026.

When H.C. Wainwright published its rating, Halozyme Therapeutics' share price was $109.22. The stock is currently trading at $109.16, with a 52-week range between $61.23 and $109.66. The company has a market capitalization of approximately $12.95 billion.